TuHURA Biosciences (HURA) Cash & Equivalents (2010 - 2026)

TuHURA Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 1.29% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 1.29% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, down 71.4% from the prior year.
• Cash & Equivalents grew to $6.3 million in Q1 2026 per HURA's latest filing, from $3.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.7 million in Q4 2024 and bottomed at $216000.0 in Q3 2023.
• The 5-year median for Cash & Equivalents is $4.9 million (2024), against an average of $5.6 million.
• Across the five-year window, Cash & Equivalents sank 96.95% in 2023 and soared 1298.15% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $4.9 million in 2022, then slipped by 24.8% to $3.7 million in 2023, then soared by 245.35% to $12.7 million in 2024, then plunged by 71.4% to $3.6 million in 2025, then soared by 74.04% to $6.3 million in 2026.
• Per Business Quant, the three latest HURA Cash & Equivalents figures stand at $6.3 million (Q1 2026), $3.6 million (Q4 2025), and $2.7 million (Q3 2025).